The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CMIC Co., Ltd.; Daiichi Sankyo; eChainaHealth,Inc.; Elevation Oncology; Elevation Oncology; Gilead Sciences; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Leap Therapeutics; Levolution Medicines,Inc.; Moderna.Inc; MSD; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Phanes Therapeutics; Sanofi; Scandion Oncology; Suzuhou Liangyihui Network Technology Co.,; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Insyte Biosciences G.K., (Inst); Medpace Japan K.K., (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Hirokazu Shoji
Consulting or Advisory Role - Astellas Pharma
Research Funding - AbbVie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Elevation Oncology (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Nicola Fazio
Honoraria - Astellas Pharma; Merck Serono; Novartis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Esteve; Ipsen; ITM Isotope Technologies Munich; Merck Serono; MSD Oncology; Novartis
Research Funding - Ipsen (Inst); Merck Serono (Inst); Novartis
Other Relationship - Astellas Pharma (Inst); Astellas Pharma (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Celltrion; Merck KGaA; MSD Oncology; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; BeiGene; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; PIN therapeutics; Takeda
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avelos Therapeutics (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genome & Company (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IDRx (Inst); IgM Biosciences (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Jazz Pharmaceuticals (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Leap Therapeutics (Inst); Medicenna (Inst); MedPacto (Inst); Merck KGaA (Inst); Metafines (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Panolos Bioscience (Inst); Pfizer (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Torl Biotherapeutics (Inst); Trishula Therapeutics (Inst); Wellmarker Bio (Inst); Yuhan (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Li-Yuan Bai
Honoraria - Ipsen; Ono Pharmaceutical; Taiwan Society for Therapeutic Radiology and Oncology; Taiwan Society for Therapeutic Radiology and Oncology; TTY Biopharm
Consulting or Advisory Role - Amgen; Astellas Pharma
Research Funding - Eisai
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Jean-Philippe Metges
Honoraria - Amgen; Beigene; BeiGene; Gilead Sciences; MSD Oncology; Pierre Fabre; Pierre Fabre
Consulting or Advisory Role - Bayer; BeiGene; BeiGene; Daiichi Sankyo Europe GmbH; MSD Oncology
Travel, Accommodations, Expenses - BeiGene; MSD Oncology
 
Gianluca Masi
Consulting or Advisory Role - AstraZeneca; Eisai; MSD Oncology; Roche; Roche; TERUMO
Research Funding - Terumo (Inst); Terumo (Inst)
Patents, Royalties, Other Intellectual Property - Terumo (Inst)
 
Denis Smith
No Relationships to Disclose
 
Tae-Yong Kim
Consulting or Advisory Role - BeiGene; Boryung
Research Funding - AstraZeneca
 
Maria Matsangou
Employment - Astellas Pharma
 
Archita Shrivastava
Employment - Astellas Pharma
 
Miaomai Zhou
Employment - Astellas Pharma
 
Aziz Zaanan
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS GmbH & Co. KG; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Jazz Pharmaceuticals; Merck Serono; MSD; Pierre Fabre; Sanofi; SERVIER
Research Funding - Amgen
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Jazz Pharmaceuticals; Merck; MSD; Pierre Fabre; SERVIER
 
Samuel Klempner
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; EsoBiotec; Gilead Sciences; I-Mab; Merck; Novartis; Taiho Oncology
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); BeiGene (Inst); I-Mab (Inst); Leap Therapeutics (Inst); Mersana (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
(OPTIONAL) Uncompensated Relationships - Debbies Dream Foundation